PharVision Advisers’s Cars.com CARS Stock Holding History

PharVision Advisers’s Portfolio CARS Stock Details CARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15,029	Closed	-$183K	–	183
2025 Q4	$183K	Buy	+15,029	New	+$175K	0.09%	587
2025 Q2	–	Sell	-12,073	Closed	-$136K	–	290
2025 Q1	$136K	Sell	12,073 -1,530	-11%	-$23.2K	0.19%	230
2024 Q4	$236K	Buy	+13,603	New	+$238K	0.2%	241

Other funds holding CARS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PFCS

Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

HPC

Hill Path Capital New York $1.37B AUM 15.26% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

BICM

Breach Inlet Capital Management Mt. Pleasant, South Carolina $305M AUM 7.94% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PharVision Advisers's CARS Position: Q1 2026 in Review

PharVision Advisers sold out of Cars.com (CARS) in Q1 2026, closing a stake of 15,029 shares — an estimated $183K sold.

PharVision Advisers first reported a position in CARS in Q4 2024 and held it in 3 quarters. The position peaked at $236K in Q4 2024. 207 funds tracked by Wall St. Rank hold CARS as of Q1 2026.

PharVision Advisers reported no remaining Cars.com position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 15,029 Cars.com shares in Q1 2026, an estimated $183K.
PharVision Advisers first reported a position in Cars.com in Q4 2024 and held it in 3 quarters.
PharVision Advisers's Cars.com position peaked at $236K in Q4 2024.
207 funds tracked by Wall St. Rank held Cars.com as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.